Netherton Syndrome: Clinical Trials

6 trials for Netherton Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 recruiting, 2 terminated, 1 active not recruiting. 6 Phase 2, 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 26Recruiting 3, Terminated 2, Active not recruiting 1
Phase 36Recruiting 3, Terminated 2, Active not recruiting 1

Follow Netherton Syndrome: new trials by email Literature Review of Netherton Syndrome trials Research Report on Netherton Syndrome

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
QRX003 - Netherton Syndrome
Phase 2 / Phase 3RecruitingQuoin Pharmaceuticals162026-03-192026-09-28
Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
QRX003, 4% Lotion - Netherton Syndrome
Phase 2 / Phase 3RecruitingQuoin Pharmaceuticals82025-10-062026-08-31
A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome
Spesolimab - solution for infusion, Placebo matching to spesolimab - solution for infusion, Spesolimab - solution for injection - Netherton Syndrome
Phase 2 / Phase 3TerminatedBoehringer Ingelheim432023-06-122026-03-12
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
QRX003, 4% Lotion - Netherton Syndrome
Phase 2 / Phase 3RecruitingQuoin Pharmaceuticals202023-03-142026-08-31
Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome
QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle - Netherton Syndrome
Phase 2 / Phase 3Active not recruitingQuoin Pharmaceuticals302022-06-232026-03-16
A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome
Dupilumab Prefilled Syringe, Placebo Prefilled Syringe - Netherton Syndrome
Phase 2 / Phase 3TerminatedUniversity Hospital, Toulouse102020-07-232026-09-21

Broader conditions

Abnormalities, Multiple (6)  ·  Congenital Abnormalities (6)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6)  ·  Genetic Diseases, Inborn (6)  ·  Ichthyosiform Erythroderma, Congenital (6)  ·  Ichthyosis (6)  ·  Infant, Newborn, Diseases (6)  ·  Keratosis (6)  ·  Skin Abnormalities (6)  ·  Skin Diseases (6)  ·  Skin Diseases, Genetic (6)  ·  Skin and Connective Tissue Diseases (6)

Interventions

Injections (1)  ·  spesolimab (1)

Sponsors

Quoin Pharmaceuticals (4)  ·  Boehringer Ingelheim (1)  ·  University Hospital, Toulouse (1)

Countries

United States (5)  ·  France (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Bulgaria (1)  ·  China (1)  ·  Germany (1)  ·  Israel (1)  ·  Italy (1)  ·  Japan (1)  ·  Malaysia (1)  ·  Netherlands (1)  ·  Portugal (1)  ·  Switzerland (1)

Top investigators

Tony Andrasfay (2)